Therapy Detail

Therapy Name Altiratinib
Synonym
Therapy Description

Altiratinib (DCC-2701) is an inhibitor of MET, VEGFR2, TIE2, and Trk that decreases endothelial cell survival and may inhibit cell proliferation and increase cell death in tumors expressing these factors (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Altiratinib DCC-2701 MET Inhibitor 51 Trk Receptor Inhibitor (Pan) 23 Altiratinib (DCC-2701) is an inhibitor of MET, VEGFR2, TIE2, and Trk that decreases endothelial cell survival and may inhibit cell proliferation and increase cell death in tumors expressing these factors (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET act mut Advanced Solid Tumor sensitive Altiratinib Preclinical - Cell culture Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited MET activity, including MET activating mutations, and inhibited proliferation of MET-driven tumor cell lines in culture (PMID: 26285778). 26285778
FLT3 exon 14 ins acute myeloid leukemia sensitive Altiratinib Preclinical - Cell culture Actionable In a preclinical study, Altiratinib (DCC-0701) inhibited proliferation of an acute myeloid leukemia cell harboring a FLT3-ITD mutation in culture (PMID: 26285778). 26285778
MET D1228N Advanced Solid Tumor predicted - sensitive Altiratinib Preclinical Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228N in an in vitro kinase assay (PMID: 26285778). 26285778
MET amp MET over exp stomach cancer sensitive Altiratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Altiratinib (DCC-0701) inhibited Met phosphorylation and proliferation of a gastric cancer cell line with MET amplification and over expression in culture, and inhibited tumor growth and induced tumor regression in xenograft models (PMID: 26285778). 26285778
MET amp MET over exp non-small cell lung carcinoma sensitive Altiratinib Preclinical - Cell culture Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and proliferation of a non-small cell lung cancer cell line with MET amplification and overexpression in culture (PMID: 26285778). 26285778
MET Y1230C Advanced Solid Tumor predicted - sensitive Altiratinib Preclinical Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230C in an in vitro kinase assay (PMID: 26285778). 26285778
MET positive ovarian cancer predicted - sensitive Altiratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited MET activation, decreased viability and migration of c-MET positive ovarian cancer cells in culture, and reduced tumor growth in ovarian cancer cell line xenograft models (PMID: 24362531). 24362531
MET D1228H Advanced Solid Tumor predicted - sensitive Altiratinib Preclinical Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228H in an in vitro kinase assay (PMID: 26285778). 26285778
MET Y1230D Advanced Solid Tumor predicted - sensitive Altiratinib Preclinical Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230D in an in vitro kinase assay (PMID: 26285778). 26285778
MET positive glioblastoma multiforme predicted - sensitive Altiratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited viability of several MET-expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451). 26965451
ETV6-NTRK3 Advanced Solid Tumor sensitive Altiratinib Preclinical Actionable In a preclinical study, transformed cells expressing ETV6-NTRK3 demonstrated sensitivity to Altiratinib (DCC-2701) in culture, resulting in inhibition of Ntrk3 phosphorylation and decreased cell proliferation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 790). detail...
MET M1250T Advanced Solid Tumor predicted - sensitive Altiratinib Preclinical Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET M1250T in an in vitro kinase assay (PMID: 26285778). 26285778
MET over exp glioblastoma multiforme predicted - sensitive Altiratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and viability of several Met over expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451). 26965451
Unknown unknown breast cancer not applicable Altiratinib Preclinical Actionable In a preclinical study, Altiratinib (DCC-0701) inhibited tumor growth and decreased lung metastasis in a mouse breast cancer model (PMID: 26285778). 26285778
MET Y1230H Advanced Solid Tumor predicted - sensitive Altiratinib Preclinical Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230H in an in vitro kinase assay (PMID: 26285778). 26285778
Clinical Trial Phase Therapies Title Recruitment Status
NCT02228811 Phase I Altiratinib A Study of DCC-2701 in Participants With Advanced Solid Tumors Terminated